CN101925352B - 包含烟碱型激动剂的组合物及其使用方法 - Google Patents

包含烟碱型激动剂的组合物及其使用方法 Download PDF

Info

Publication number
CN101925352B
CN101925352B CN200880126096.9A CN200880126096A CN101925352B CN 101925352 B CN101925352 B CN 101925352B CN 200880126096 A CN200880126096 A CN 200880126096A CN 101925352 B CN101925352 B CN 101925352B
Authority
CN
China
Prior art keywords
nicotine
nicotinic
nicotinic agonist
disease
opipramol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880126096.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN101925352A (zh
Inventor
E·赫尔德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuroderm Ltd
Original Assignee
Neuroderm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40380297&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101925352(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neuroderm Ltd filed Critical Neuroderm Ltd
Publication of CN101925352A publication Critical patent/CN101925352A/zh
Application granted granted Critical
Publication of CN101925352B publication Critical patent/CN101925352B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN200880126096.9A 2007-11-26 2008-11-26 包含烟碱型激动剂的组合物及其使用方法 Expired - Fee Related CN101925352B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99016107P 2007-11-26 2007-11-26
US60/990,161 2007-11-26
PCT/IL2008/001546 WO2009069126A1 (en) 2007-11-26 2008-11-26 Compositions comprising nicotinic agonists and methods of using same

Publications (2)

Publication Number Publication Date
CN101925352A CN101925352A (zh) 2010-12-22
CN101925352B true CN101925352B (zh) 2016-03-16

Family

ID=40380297

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880126096.9A Expired - Fee Related CN101925352B (zh) 2007-11-26 2008-11-26 包含烟碱型激动剂的组合物及其使用方法

Country Status (21)

Country Link
US (5) US8273731B2 (enExample)
EP (1) EP2224917B1 (enExample)
JP (1) JP5456687B2 (enExample)
KR (1) KR101613742B1 (enExample)
CN (1) CN101925352B (enExample)
AR (1) AR069752A1 (enExample)
AU (1) AU2008331102B2 (enExample)
BR (1) BRPI0819911A2 (enExample)
CA (1) CA2744736C (enExample)
CL (1) CL2008003507A1 (enExample)
CY (1) CY1119768T1 (enExample)
DK (1) DK2224917T3 (enExample)
ES (1) ES2642873T3 (enExample)
HR (1) HRP20171476T1 (enExample)
HU (1) HUE035105T2 (enExample)
LT (1) LT2224917T (enExample)
MX (1) MX2010005804A (enExample)
PL (1) PL2224917T3 (enExample)
PT (1) PT2224917T (enExample)
SI (1) SI2224917T1 (enExample)
WO (1) WO2009069126A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
KR101563554B1 (ko) 2008-08-01 2015-10-27 퀄컴 테크놀로지스, 인크. 잡음 제거를 위한 통합 시간 필터를 구비한 비디오 인코더
US9801865B2 (en) * 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
US8529914B2 (en) * 2010-06-28 2013-09-10 Richard C. Fuisz Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive
SMT202100228T1 (it) 2011-04-29 2021-05-07 Moberg Pharma Ab Composizioni farmaceutiche comprendenti un anestetico locale come bupivacaina per somministrazione locale alla bocca o alla gola
EP2872899B1 (en) * 2012-07-13 2018-07-11 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patient
CN106413754B (zh) 2014-03-13 2019-11-29 纽罗德姆有限公司 多巴脱羧酶抑制剂组合物
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
US20170216273A1 (en) * 2014-05-29 2017-08-03 Jory F. Goodman Nicotine Derivatives and Methods of Use
RU2017111271A (ru) * 2014-09-18 2018-10-18 Нейродерм, Лтд. Опипрамоловый пластырь
US9504645B2 (en) * 2014-10-20 2016-11-29 Oyster Point Pharma, Inc. Pharmaceutical formulations for treating ocular conditions
EP3226704B1 (en) 2014-12-05 2021-01-20 Juul Labs, Inc. Calibrated dose control
US10709707B2 (en) 2016-04-07 2020-07-14 Oyster Point Pharma, Inc. Methods of treating ocular conditions
US10292977B2 (en) * 2016-04-11 2019-05-21 Neurocea, LLC Compositions and methods for treatment related to fall and fall frequency in neurodegenerative diseases
HK1258883A1 (zh) 2016-04-12 2019-11-22 A‧索利斯‧赫雷拉 用烟硷乙酰胆硷受体激动剂治疗鼻和鼻旁粘膜病症的组合物和方法
KR20180058644A (ko) * 2016-11-24 2018-06-01 에스케이케미칼 주식회사 바레니클린 서방성 제제 및 이의 제조 방법
US11260050B2 (en) 2017-02-16 2022-03-01 United States Government As Represented By The Department Of Veterans Affairs Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological
US20200000822A1 (en) * 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
US10961296B2 (en) 2017-11-10 2021-03-30 Howard Hughes Medical Institute Modified ligand-gated ion channels and methods of use
LU101519B1 (en) * 2019-12-02 2021-06-07 Herrera Arturo Solis (S)-3-[1-MethyIpyrrolidin-2-yl]pyridine, analogues thereof, precursors thereof, or its derivatives, for the use as a pharmaceutical in form of a solid substance and a tablet
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1423556A (zh) * 2000-04-15 2003-06-11 Lts罗曼治疗方法有限公司 用于戒除烟瘾的具有含尼古丁活性物质组合物的经皮肤或经粘膜给药剂型
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069094A (en) * 1987-09-08 1991-12-03 Birkestrand Orville J Tube end finishing machine
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5668117A (en) 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
NZ252618A (en) * 1992-05-18 1996-04-26 Pharmaco Behavioral Ass Use of cotinine to alleviate tobacco withdrawal syndrome
JPH09262287A (ja) * 1996-03-28 1997-10-07 Terumo Corp 薬液注入装置
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
WO2002011768A1 (en) * 2000-08-03 2002-02-14 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
US6479076B2 (en) * 2001-01-12 2002-11-12 Izhak Blank Nicotine delivery compositions
DE10134038A1 (de) 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
US20030119879A1 (en) * 2001-10-15 2003-06-26 Thomas Landh Nicotine and chocolate compositions
US6852741B2 (en) * 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US7045534B2 (en) * 2002-02-12 2006-05-16 The Board Of Trustees Of The Leland Stanford Junior University Methods of reducing angiogenesis
US20040161481A1 (en) * 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
ITMI20030828A1 (it) 2003-04-18 2004-10-19 Farchemia Srl Procedimento per la preparazione dell'opipramolo.
ATE534373T1 (de) * 2003-10-10 2011-12-15 Antares Pharma Ipl Ag Transdermale pharmazeutische formulierung zur minimierung von rückständen auf der haut
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
WO2005115471A2 (en) 2004-05-27 2005-12-08 Neurocure Ltd. Methods and compositions for treatment of nicotine dependence and dementias
US20060142349A1 (en) * 2004-12-23 2006-06-29 Pfizer Inc Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor
US20080014252A1 (en) * 2006-07-14 2008-01-17 Delprete Keith Topical compositions with long lasting effect
WO2008011484A2 (en) 2006-07-18 2008-01-24 Bethesda Pharmacology Associates, Llc Nicotinic desensitizers and methods of selecting, testing, and using them
EP2083921A2 (en) * 2006-09-04 2009-08-05 Neurosearch A/S Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
CL2008003507A1 (es) 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1423556A (zh) * 2000-04-15 2003-06-11 Lts罗曼治疗方法有限公司 用于戒除烟瘾的具有含尼古丁活性物质组合物的经皮肤或经粘膜给药剂型
US20050234024A1 (en) * 2004-04-14 2005-10-20 Clarke David E Materials and methods for the treatment of ulcerative colitis

Also Published As

Publication number Publication date
MX2010005804A (es) 2010-11-30
PT2224917T (pt) 2017-10-17
JP5456687B2 (ja) 2014-04-02
AU2008331102B2 (en) 2014-04-10
US8273731B2 (en) 2012-09-25
LT2224917T (lt) 2017-12-27
US20090149446A1 (en) 2009-06-11
ES2642873T3 (es) 2017-11-20
AR069752A1 (es) 2010-02-17
CY1119768T1 (el) 2018-06-27
SI2224917T1 (sl) 2017-12-29
CL2008003507A1 (es) 2009-11-27
US20130172321A1 (en) 2013-07-04
US20180303818A1 (en) 2018-10-25
KR20100105841A (ko) 2010-09-30
EP2224917B1 (en) 2017-07-05
US8921356B2 (en) 2014-12-30
HUE035105T2 (en) 2018-05-02
PL2224917T3 (pl) 2018-02-28
DK2224917T3 (en) 2017-10-16
CA2744736A1 (en) 2009-06-04
KR101613742B1 (ko) 2016-04-19
US20170128432A1 (en) 2017-05-11
CN101925352A (zh) 2010-12-22
JP2011504490A (ja) 2011-02-10
EP2224917A1 (en) 2010-09-08
BRPI0819911A2 (pt) 2017-06-13
HRP20171476T1 (hr) 2017-12-15
CA2744736C (en) 2015-06-09
US20150306109A1 (en) 2015-10-29
WO2009069126A1 (en) 2009-06-04
AU2008331102A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
CN101925352B (zh) 包含烟碱型激动剂的组合物及其使用方法
AU2009219546A1 (en) Kit, composition, product or medicament for treating cognitive impairment
DE69926804T2 (de) Vorrichtungen zur behandlung und diagnose des restless leg syndroms
AU2007212349A1 (en) 4-acylaminopyridine derivative mediated neurogenesis
US10596139B2 (en) Oxybutynin transdermal therapeutic system muscarinic agonist combination
JP2006519225A (ja) 依存症治療用医薬組成物
HK1148209A (en) Composition comprising nicotine and opipramol and use thereof
HK1148209B (en) Composition comprising nicotine and opipramol and use thereof
CN109562180B (zh) 组胺-3受体反向激动剂、乙酰胆碱酯酶抑制剂和nmda受体拮抗剂的三重组合产品
US9492543B2 (en) Compositions for treating cognitive disorders
Valdman P. 5.005 Novel antiparkinsonian drug hemantane
MX2008010252A (en) 4-acylaminopyridine derivative mediated neurogenesis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160316

Termination date: 20181126